Evercore ISI Group Maintains In-Line on Augmedix, Lowers Price Target to $4.5
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Elizabeth Anderson maintains an In-Line rating on Augmedix (NASDAQ:AUGX) and lowers the price target from $6.5 to $4.5.
March 19, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Evercore ISI Group maintains an In-Line rating on Augmedix and lowers the price target from $6.5 to $4.5.
The reduction in price target by Evercore ISI Group, a reputable analyst firm, could lead to a negative perception among investors regarding Augmedix's future financial performance or growth prospects, potentially causing a short-term decrease in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100